. . . . . . . . . "2010-5-17" . "Castration resistant prostate cancer (CRPC) develops as a consequence of hormone therapies used to deplete androgens in advanced prostate cancer patients. CRPC cells are able to grow in a low androgen environment and this is associated with anomalous activity of their endogenous androgen receptor (AR) despite the low systemic androgen levels in the patients. Therefore, the reactivated tumor cell androgen signaling pathway is thought to provide a target for control of CRPC. Previously, we reported that Hedgehog (Hh) signaling was conditionally activated by androgen deprivation in androgen sensitive prostate cancer cells and here we studied the potential for cross-talk between Hh and androgen signaling activities in androgen deprived and androgen independent (AI) prostate cancer cells." . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "eng" . . "IM" . . . . . . . . . "MEDLINE" . "1476-4598" . . . . . . . . . . . . "Electronic" . "9" . "NLM" . "Y" . "89" . "2010-9-28" . . . . . . . . . . . . . . . . . . . "2010" . "Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells." . "The Ordway Research Institute, Albany, New York, USA." . "Journal Article" . "Research Support, U.S. Gov't, Non-P.H.S." . "Research Support, Non-U.S. Gov't" . "Research Support, N.I.H., Extramural" .